It strikes me some people selling Sbtx are a little bit silly. I guess the majority are traders and we know the majority are running a net loss annually, so why not allow dead certs like Sbtx run and build those profits.
It's funny watching netcurtains on lse tie himself in knots with what he claims to be a delayed launch when everyone else had got over it after the clinical study was known to have given a green light to launch.
You can't find it outside the chat thread because you responded to a short clip that is not in this thread. Substack is not very user-friendly unless you are quite familiar with it.
I'll repeat my answer here to put you out of your misery.
It’s entirely possible. Unlikely, at this stage, for the reasons discussed, and I’m sure there are many more. It would seriously limit the reach of Zenakine if one global entity acquired it. Hence, the antitrust legislation could be a problem.
Gentlemen, while there are several factors at play, the crux of John's point was that the window for Croda to make a decisive move, prior to the option to acquire SBTX’s SkinBiotix platform outright must necessarily be a narrow one.
Elric,Mike Powder Monkey and David Brierwood, have to be the next podcast. Alex get to work!
Hey John, thank you for sharing you insights.
It strikes me some people selling Sbtx are a little bit silly. I guess the majority are traders and we know the majority are running a net loss annually, so why not allow dead certs like Sbtx run and build those profits.
It's funny watching netcurtains on lse tie himself in knots with what he claims to be a delayed launch when everyone else had got over it after the clinical study was known to have given a green light to launch.
Commented earlier, but now can’t find it.
What i was saying was couldn’t L’Oréal make a bid for skinbiotherapeutics, instead of Croda,
Taking royalties from Croda, buying Zenakine at cost, and avoiding any monopoly, antitrust issues in the process?
You can't find it outside the chat thread because you responded to a short clip that is not in this thread. Substack is not very user-friendly unless you are quite familiar with it.
I'll repeat my answer here to put you out of your misery.
It’s entirely possible. Unlikely, at this stage, for the reasons discussed, and I’m sure there are many more. It would seriously limit the reach of Zenakine if one global entity acquired it. Hence, the antitrust legislation could be a problem.
Insightful.
Gentlemen, while there are several factors at play, the crux of John's point was that the window for Croda to make a decisive move, prior to the option to acquire SBTX’s SkinBiotix platform outright must necessarily be a narrow one.